# Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

> **NCT00003552** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Stage IV Melanoma
- Recurrent Melanoma

## Interventions

- **DRUG:** allogeneic lymphocytes
- **DRUG:** anti-thymocyte globulin
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine

## Key facts

- **NCT ID:** NCT00003552
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-01
- **Primary completion:** —
- **Final completion:** 2002-10
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003552, "Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00003552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*